Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Platyhelminth voltage-gated calcium channel (VGCC) beta subunits are essential auxiliary proteins that regulate the activity and plasma membrane expression of the pore-forming alpha-1 subunit (Jeziorski & Greenberg, 2006). In parasitic flatworms such as Schistosoma mansoni, these subunits exist in two forms: a conventional beta subunit and a unique variant beta subunit (Cavbeta-var) (Kohn et al., 2001). The variant subunit is of particular therapeutic interest as it is found exclusively in platyhelminths and has been identified as a primary molecular target for praziquantel, the gold-standard treatment for schistosomiasis and other trematode and cestode infections (Nogi et al., 2009). These subunits are critical for maintaining calcium homeostasis, which in turn controls muscle contraction, neuronal signaling, and tegumental integrity in the parasite (Greenberg, 2005). Praziquantel and related drugs like epsiprantel interact with the VGCC complex, specifically through the variant beta subunit, to induce a rapid and sustained influx of calcium ions into the parasite's cells (Jeziorski & Greenberg, 2006). This sudden increase in intracellular calcium leads to intense muscle contraction, spastic paralysis, and damage to the parasite's tegument, ultimately resulting in its death or clearance by the host's immune system (Kohn et al., 2001). Because these variant subunits are structurally distinct from vertebrate calcium channel subunits, they provide a basis for the drug's high selectivity and low toxicity in human hosts (Greenberg, 2005). Research into these subunits continues to be vital for understanding drug resistance and developing next-generation anthelmintics (Nogi et al., 2009).
Allosteric activation of the voltage-gated calcium channel complex through interaction with the beta subunit, leading to massive calcium influx and spastic paralysis.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Platyhelminth voltage-gated calcium channel beta subunit (Cavbeta).